Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer’s disease - Rabal, O; Sánchez-Arias, JA; Cuadrado-Tejedor, M (J Med Chem, 2016)
et al.